Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

In Memoriam: Calvin R. Brown Jr., MD

Eric Ruderman, MD  |  

Calvin R. Brown Jr., MD, of Chicago, passed away Dec. 1, 2019. He was 66 years old. In the course of a medical career, you meet dozens of people who impact you in one way or another. Patients, professors, fellow students, colleagues in your practice—all help shape who we become as a physician. Sometimes, though,…

Even with Insurance, Fewer Americans Seeing Primary Care Providers

Lisa Rapaport  |  

(Reuters Health)—Almost half of U.S. adults with private health insurance are not visiting primary care providers for routine care or sick visits, a new study suggests. Between 2008 and 2016, the number of annual primary care visits for every 100 people with private health insurance declined by 22%, from 169.5 to 134.3, the study found….

Update on the Management of Takayasu Arteritis

  |  

A rare form of large vessel vasculitis, Takayasu arteritis persents with no clear patterns, with patients experiencing vascular symptoms, as well as such systemic symptoms as fever and weight loss. A systematic literature review found evidence to guide rheumatologists in monitoring and treating their patients with Takayasu arteritis…

Biologic Spending & Price Trends

Arthritis & Rheumatology  |  

Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…